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The role of the hexosamine biosynthetic pathway in diabetic decline in renal function in type 1 and type 2 diabetes
nephropathy. The hexosamine biosynthetic pathway has been derived from an increase in mesangial matrix [2–5]. Im-
hypothesized to be involved in the development of insulin munohistochemical and biochemical studies indicated anresistance and diabetic vascular complications. In particular, it
increased deposition of various collagen types, laminin,was demonstrated that hyperglycemia-induced production of
and fibronectin, particularly in glomeruli of patients withtransforming growth factor-b (TGF-b1), a prosclerotic cyto-
kine causally involved in the development of diabetic nephrop- diabetes and in experimental animal models [6–11]. Nu-
athy. Several lines of evidence indicate that TGF-b1 induction merous studies have shown that elevated glucose concen-
is mediated by the hexosamine pathway. In cultured mesangial trations can cause an increased expression of these com-
cells, high glucose levels induce TGF-b1 production. This effect
ponents of the extracellular matrix in cultured mesangialis eliminated by inhibition of glutamine : fructose-6-phosphate-
cells, which suggests that these cells are an useful modelamidotransferase (GFAT), the rate-limiting enzyme of this path-
way. Furthermore, stable overexpression of GFAT increased in studying the pathogenesis of diabetic nephropathy
levels of TGF-b1 protein, mRNA, and promoter activity. Inas- [10, 12, 13]. These in vitro studies provided evidence that
much as stimulation or inhibition of GFAT increased or de- the high glucose-induced stimulation of mesangial and
creased high glucose-stimulated activity of protein kinase C
tubular matrix production is mediated by transforming(PKC), respectively, the observed effects appear to be trans-
growth factor-b1 (TGF-b1) [14–17]. Early glomerular andduced by PKC. In similar experiments, involvement of the
hexosamine pathway in hyperglycemia-induced production of tubular increase of TGF-b1 expression has been shown
cytokines (TGF-a and basic fibroblast growth factor [bFGF]) in experimental and human diabetic nephropathy [18–20].
was demonstrated in vascular smooth muscle cells. These stud- A causal involvement of TGF-b was also demonstrated
ies also revealed a rapid increase in GFAT activity by treatment given that application of TGF-b-antibodies attenuatedwith agents that elevated levels of cyclic adenosine 39,59 mono-
the effects in cultured mesangial cells [15] and in experi-phosphate (cAMP), thus indicating that GFAT activity is tightly
regulated by cAMP-dependent phosphorylation. Using immu- mental animals [21]. These studies indicate that elevated
nohistochemistry and in situ hybridization, high expression of glucose levels induce cytokine production, particularly
GFAT was found in human adipocytes, skeletal muscle, vascu- that of TGF-b1, which in turn induces renal extracellular
lar smooth muscle cells, and renal tubular epithelial cells,
matrix synthesis and finally leads to renal scarring. Dif-whereas glomerular cells remained essentially unstained. How-
ferent pathobiochemical pathways are thought to be in-ever, significant staining occurred in glomerular cells of patients
with diabetic nephropathy. Current data indicate that the flux volved in these damaging events. These include: the sor-
through the hexosamine pathway, regulated by GFAT, may bitol pathway, oxidative stress, the formation and action
be causally involved in the development of diabetic vascular of AGE-products and activation of protein kinase C
disease, particularly diabetic nephropathy.
(PKC) [22] and other kinases. Investigation of the speci-
ficity of the high glucose effect revealed that D-glucos-
amine but not other related hexoses efficiently mimickedDuring development of diabetic nephropathy, the re-
the effect in stimulating TGF-b1 production in mesangialnal arterioles, tubules, interstitium, and particularly the
cells [23] and production of TGF-a and basic fibroblastglomeruli undergo structural changes that include hyali-
growth factor (bFGF) in vascular smooth muscle cellsnosis of arteriolar wall, thickening of the glomerular and
[24]. In combination, these studies have indicated thattubular basement membranes, and extension of the mes-
the hexosamine biosynthetic pathway may be involvedangial matrix [1, 2]. Quantitative morphometric studies
in mediating the effects of high levels of glucose.have shown that the changes most closely related to the
HEXOSAMINE BIOSYNTHETIC PATHWAYKey words: transforming growth factor, hyperglycemia, glutamine : fruc-
tose-6-phosphate-amidotransferase, gene expression. Amino sugars are physiologically synthesized through
the hexosamine biosynthetic pathway (Fig. 1). In this path-Ó 2000 by the International Society of Nephrology
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Fig. 1. The hexosamine biosynthetic pathway. Glucose (Gluc) enters the cell through the glucose transporter and is metabolized. The hexosamine
biosynthetic pathway merges from glycolysis using fructose-6-phosphate (Fruc-6-P) to form glucosamine-6-P (GlucN-6-P). Glutamine (GluN)
serves as donor of the aminogroup. The reaction is catalyzed by the rate-limiting enzyme glutamine : fructose-6-phosphate-amidotransferase (GFAT).
GlucN-6-P is rapidly acetylated, isomerized to N-Acetylglucosamine-6-phosphate (GlucNAc-1-P) and activated to UDP-N-acetylglucosamine (UDP-
GlucNAc) that serves as common precursor for all amino sugars used for the synthesis of glycoproteins, -lipids, and proteoglycans. Glucosamine
(GlucN) can also enter the cell through the glucose transporter and is rapidly phosphorylated by hexokinase yielding GlucN-6-P, thereby bypassing
the rate-limiting first step of the hexosamine biosynthetic pathway.
way, fructose-6-phosphate is converted to glucosamine-6- mine pathway, inhibition of this pathway by either inhibi-
tion of GFAT synthesis using, for example, antisensephosphate (GlucN-6-P) by the rate-limiting enzyme glut-
amine : fructose-6-phosphate-amidotransferase (GFAT), technology or by application of glutamine analogs, such
as azaserine or diazo-oxo-norleucin, may be applied [23,which uses glutamine as an amino donor [25, 26]. GlucN-
6-P is rapidly converted further and activated to uridine- 26, 27]. Most glucose taken up by the cells is metabolized
through glycolysis; only 2% to 5% enters the hexosamine5-diphosphate-N-acetylglucosamine (UDP-GlucNAc).
UDP-GlucNAc is the precursor for all other amino sug- pathway. It appears that the amount of glucose entering
this pathway is regulated by GFAT activity. Therefore,ars that are necessary for the biosynthesis of glycopro-
teins, glycolipids, proteoglycans, and glycosaminoglycans. it is not unexpected that GFAT is highly regulated. The
major points of regulation are (1) the concentration ofBecause glucosamine levels of extracellular fluids are
below the limit of detection (i.e., ,0.02 mmol/L), cellular fructose-6-phosphate is important because the affinity
for the GFAT substrate is low (i.e., in the 3 to 10 mmol/Luptake of glucosamine may be neglected under physio-
logic conditions. However, if glucosamine is added to cells, range); (2) GFAT activity is feedback-inhibited by its
downstream product UDP-GlucNAc through an alloste-it is avidly taken up by the glucose transporter and phos-
phorylated by hexokinase yielding GlucN-6-P, thereby ric mechanism [29]; (3) GFAT activity can be influenced
by the quantity of GFAT protein in the cell [30]; andbypassing the rate-limiting enzyme GFAT. Thus, use of
glucosamine represents a method to mimic the high glu- (4) GFAT activity is increased by 39,59 monophosphate
(cAMP)-dependent phosphorylation [31]. Given that thecose effects that are mediated by the hexosamine pathway
[23–28]. However, for unequivocal evidence that the ef- latter regulation of GFAT activity is rapid and occurs
within 10 minutes, it may be important for fast regulationfects of high glucose levels are mediated by the hexosa-
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Table 1. Properties of glutamine : fructose-6-phosphate- more potent than glucose in stimulating TGF-b1 tran-
amidotransferase (GFAT)
scription in cultured renal proximal tubular cells (ab-
Oligomers in eukaryotes stract; Daniels MC, J Am Soc Nephrol 6:1040, 1995).
Monomer 77 kD molecular weight These data indicate that the flux of glucose metabolismFeedback inhibition by UDP-GlucNAc
through the GFAT-catalyzed hexosamine biosyntheticHigh Km for both substrates
High homology (yeast, mouse, man) pathway mediates the hyperglycemia-induced renal pro-
Regulated by cAMP-dependent phosphorylation duction of TGF-b leading to renal matrix expansion.Two isoforms (GFAT 1 and 2)
To elucidate further the involvement of the hexosa-Chromosomal location GFAT1: 2p13i; GFAT2: 5q
mine pathway in TGF-b1 induction, human GFAT was
stably overexpressed in NIH-3T3 fibroblasts, yielding
a 2.5-fold increase in GFAT protein as determined by
Western blot (Weigert and Schleicher, unpublished re-of the flux through the hexosamine pathway. The flux
through the hexosamine pathway may also be regulated sults). To verify that the hexosamine pathway was acti-
vated by GFAT overexpression, cellular concentrationsby GFAT gene expression. Little is known about the
half-life of GFAT protein in vivo, but studies in isolated of UDP-GlucNAc were determined by capillary electro-
phoresis as previously described [38]. A twofold increaseadipocytes suggest a half-life of less than 1 hour [32]. To
elucidate regulation of gene expression, the promoter of in UDP-GlucNAc concentration indicated increased flux
through the hexosamine pathway after 24 hours (Fig. 2A),mouse GFAT has been cloned and partially character-
ized [33]. Detailed analysis of the GC-boxes indicated whereas no difference could be found after 48 hours.
Determination of TGF-b1 expression in these cells re-that Sp1 binds to three elements and that this transcrip-
tion factor plays an important role in the regulation of vealed that TGF-b1 mRNA increased approximately
twofold after 24 hours (Fig. 2B). Although productionGFAT gene expression. Earlier studies have shown that
GFAT gene transcription can be regulated by epidermal of mesangial TGF-b1 protein was low in the first 24
hours, GFAT overexpressing cells showed a twofold pro-growth factor, glucose and glucosamine in human cells
[34] and may be increased by a-pheromone in yeast [35]. duction after 24 and 48 hours (Fig. 2C). The effect of
GFAT overexpression on TGF-b1 gene expression wasThe GFAT gene has been localized on chromosome
2p13 [36]. Recently, the existence of a second GFAT also studied by using the human TGF-b1 promoter [39]
ligated to the reporter gene luciferase. With this sensitive(GFAT2) was deduced from human cDNA showing
75.6% homology to GFAT1 [37]. The properties of GFAT assay, we were able to demonstrate that GFAT overex-
pressing cells exhibit approximately a 50% increase inare summarized in Table 1.
TGF-b1 promoter activity (Weigert and Schleicher, un-
Involvement of the hexosamine pathway in published results). These results further support the
high-glucose-level induced TGF-b1 production involvement of the hexosamine pathway in the gene reg-
ulation of TGF-b1.Investigation of the specificity of the effect of high glu-
cose on mesangial cells showed that the effect is specific Given that PKC has been implicated in the develop-
ment of late complications of diabetes [12, 13, 40], thefor D-glucose, whereas L-glucose, sorbitol, and 3-O-
methyl-D-glucose produced no effect [23]. However, effect of the hexosamine pathway on mesangial PKC has
been studied [41]. Exposure to 12 mmol/L glucosamine12 mmol/L D-glucosamine was much more potent than
30 mmol/L D-glucose itself in enhancing the production resulted in rapid and specific translocation of PKC isoen-
zymes PKC a, b, and e whereas PKC j was unaffected.of TGF-b1 protein and subsequent mesangial production
of matrix components. D-glucosamine also promoted Glucosamine similarly induced the translocation of these
PKC isoforms as rapidly and effectively as the widelyconversion of latent TGF-b to the active form. These
data indicated that the hexosamine biosynthetic pathway used PKC stimulator phorbol myristate acetate. Treat-
ment of mesangial cells with high glucose caused a trans-is involved in high glucose-level-induced mesangial
TGF-b1 production. To prove the involvement of this location of PKC b whereas other isoforms were less af-
fected. The presence of azaserine, an inhibitor of GFATpathway, GFAT activity was blocked by the substrate
analog azaserine and by inhibition of GFAT protein activity, ameliorated the effect of high glucose levels on
PKC b translocation. These data also indicate that thesynthesis with antisense-oligonucleotide. Both interven-
tions prevented the high glucose-level-induced increase high glucose level-induced activation that has been de-
scribed by various researchers [12, 13, 40] may be medi-in cellular glucosamine metabolites, TGF-b1 mRNA,
protein and bioactivity and the subsequent effects on ated by the hexosamine pathway. In a report by Filippis
et al [42], the effect of high glucose and glucosamine onenhanced matrix production. As expected, inhibition of
GFAT activity did not abolish the glucosamine-induced PKC activity was studied in adipocytes. Both high glu-
cose and glucosamine caused a threefold increase in PKCeffects because glucosamine bypasses the GFAT-cata-
lyzed step. Similarly, glucosamine has been shown to be activity; the effect of high glucose, but not that of glucos-
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Fig. 2. Overexpression of GFAT in NIH-3T3 fibroblasts increases cellular UDP-GlucNAc concentration (A), TGF-b1 mRNA (B), and TGF-b1
protein levels (C). Fibroblasts were stably transfected with the expression vector pcDNA3 containing the human GFAT cDNA under control of
the cytomegalovirus promoter or pcDNA3 alone as control. (A) Stably transfected fibroblasts were cultured for 24 or 48 hours in Dulbecco’s
modified Eagle’s medium 2% Ultroser (Gibco, Eggenstein, Germany). Preparation of cell extracts and determination of UDP-GlucNAc with
capillary electrophoresis were previously described [38]. DNA content of the cells was determined by fluorometry with bisbenzimidazol and used
for normalization of cell number [23]. (B) Stably transfected fibroblasts were cultured for 24 hours as described in (A) and total RNA was prepared.
Northern blotting was carried out with 25 mg RNA. For hybridization, digoxigenin-labeled RNA probes for TGF-b1 or glyceraldehyde 3-phosphate
dehydrogenase were used [23]. Three different control and GFAT clones are shown. (C) Supernatants of stably transfected fibroblasts cultured in
Dulbecco’s modified Eagle’s medium without fetal calf serum or Ultroser were collected after 24 and 48 hours, and TGF-b1 was determined by a
commercially available enzyme-linked immunosorbent assay (R & D Systems, Wiesbaden, Germany).
amine, was partially decreased by azaserine. In combina-
tion, these data indicate that an acute increase in the
Table 2. Expression of GFAT in human and rat tissues flux through the hexosamine biosynthesis pathway may
mRNA activate PKC. However, experiments performed by Dan-Protein Activity
iels et al [43] do not support a role of PKC in hexosamineTissue (human)a (human)a (rat)b (rat)c
pathway-mediated cytokine expression. They suggest aKidney ND 1 1
tubules 11 ND role for this pathway in leading to increased protein
glomeruli 2 ND glycosylation, particularly the transcription factor Sp1,
Muscle 111 ND 11 1
thereby effecting gene transcription [30, 43]. An alterna-Smooth muscle cells 1/111 1/111 111 ND
Liver 1 ND 1 111 tive route of glucose-induced PKC activation, for in-
Fat 111 111 111 ND stance, through diacylglycerol has been proposed by theTestis ND ND 111 11
groups led by King [22] and Ayo [40].Colon ND ND ND 111
2, below detection limit; 1 to 1 1 1, mild to strong expression; ND, not
determined. Localization of GFAT expression in human tissues
a GFAT protein was determined by immunohistochemistry or in situ hybridiza-
Investigation of the cellular expression of GFAT istion in normal human subjects [44]
b Expression of rat GFAT mRNA was evaluated by Northern blotting [36] important because it represents the rate-limiting enzymec GFAT activity by measuring the enzyme activity in tissue extracts [45].
GFAT2 mRNA was preferentially expressed in nervous tissue (not shown) [37] of the hexosamine pathway. Expression of GFAT in
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Fig. 3. Possible pathobiochemical link be-
tween hyperglycemia and mesangial TGF-b1
production. Elevated flux through the hexo-
samine pathway results in activation of PKC.
Activated and translocated PKC in turn acti-
vates transcription factors (s) to form a com-
plex that induces transcription of TGF-b1.
Finally, TGF-b1 protein is secreted and acts
autocrine/paracrine as prosclerotic cytokine.
various tissues has been studied in normal human sub- These include induction of gene expression (e.g., growth
factors in smooth muscle cells or renal mesangial cellsjects [44]. For this immunohistochemical study, a pep-
tide-antibody raised against the C-terminus of GFAT and of leptin gene expression in muscle and fat [47]) and
the induction of insulin resistance [27]. Therefore, thiswas used. Given that GFAT1 and GFAT2 are identical
at this location, the antibody recognizes both isoen- pathway may be regarded as a glucose-sensing pathway
[47]. Two possible molecular mechanisms have been elu-zymes. This study revealed that GFAT protein expres-
sion is very different in different tissues. Strong staining cidated to explain how increased flux through this path-
way may transduce its effects by activating PKC [41, 42]was seen in all epithelia including renal tubuli or epithelial
cells whereas endothelial and glomerular cells remained alone or also by increasing glycosylation of transcription
factors thereby increasing their activity [30]. The possibleessentially unstained. Noteworthy, GFAT was signifi-
cantly expressed in vascular smooth muscle cells. Further- molecular mechanism of the hyperglycemia-induced pro-
duction of the prosclerotic cytokine TGF-b1 throughmore, GFAT was strongly expressed in adipocytes and
skeletal muscle cells, which supports the hypothesis that the hexosamine biosynthetic pathway is shown in Fig. 3.
Although recent studies have increased our knowledgethe hexosamine biosynthetic pathway may be involved in
the pathogenesis of insulin resistance. The results ob- on the regulatory function of this pathway, the relevance
for the patient with diabetes remains to be established.tained for GFAT protein expression could be confirmed
on the mRNA level using in situ hybridization. Northern
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